Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

By the end of 2024, the total number of medical and health institutions nationwide reached 1,093,551, an increase of 22,766 compared to the previous year.

Danaher reported before the opening of the market on Thursday that its second quarter revenues rose 37 percent year over year, thanks largely to steep gains from its life sciences and diagnostics businesses.

July 22, Abbott said that its Diagnostics business revenues grew 63 percent year over year in the second quarter, while its total revenues were up 39 percent.

New guidelines from WHO strongly recommend offering self-testing for hepatitis C virus (HCV) as an additional approach to HCV testing services. WHO releases the new guidelines – its first on HCV self-testing – during the International AIDS Society Conference 2021. 

Research in Sri Lanka shows more than 80 per cent of those inoculated develop antibodies capable of neutralising the virus

Agilent Technologies on Tuesday announced that it has received CE marking for the expanded use of its PD-L1 IHC 22C3 pharmDx companion diagnostic assay in patients with non-small cell lung cancer.

Runda Medical issued a performance forecast, and it is expected that the net profit attributable to shareholders of listed companies will be between 195 million yuan and 215 million yuan in the first half of 2021, an increase of 75.33% year-on-year to 93.31%.

Recently, Fosun Pharma announced that the approval of the mRNA novel coronal vaccine by the Food and Drug Administration has been basically completed, and the expert review has passed. The administrative approval stage is being stepped up at present.

On July 14, China Securities Regulatory Commission (CSRC) released the news and approved the IPO registration of Sino Biological, Inc. Sino Biological is an international reagent supplier and service provider, which specializes in recombinant protein production and antibody development.

Medix Biochemica, a global leader in critical IVD raw materials, has acquired all of the shares of Diaclone SAS ("Diaclone"). Through acquisition, Medix Biochemica broadens its portfolio of critical raw materials for the in-vitro diagnostics ("IVD") industry and expands its global network.

Today, WHO and HRP have launched a new guideline to help countries make faster progress, more equitably, on the screening and treatment of this devastating disease.